Telix Pharmaceuticals Limited (“Telix”, the “Company”) today announced the completion of the acquisition of Atlab Pharma SAS (“Atlab”).
The option to acquire Atlab for the consideration of USD $10m in cash or shares (or combination thereof, at the Company’s discretion) was disclosed in Telix’s IPO prospectus. As part of the acquisition, Telix has also renegotiated Atlab’s material background intellectual property licenses, notably with BZL Biologics LLC (“BZL”). BZL is the holder of a portfolio of patents originating from Professor Neil Bander’s laboratory at Weill Cornell Medical Centre (WCMC, NY). A summary of the final consideration paid appears later in this disclosure.